Other dual IDH1/2 inhibitors, HMPL-306 and LY3410738, demonstrated potent antileukemic effects in AML PDX models [108, 109], leading to ongoing phase 1 studies of these drugs in patients with R/R AML (NCT04764474, NCT04272957, NCT0460300). This evidence concerns the gene IDH1 and acute myeloid leukemia.